Acute disseminated encephalomyelitis, transverse myelitis, and neuromyelitis optica

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 4, 2013, Pages 944-967

  Wingerchuk, Dean M ^b   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; CARBAMAZEPINE; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; BRAIN BIOPSY; CLINICAL EVALUATION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG MEGADOSE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROGNOSIS; RELAPSE; REVIEW; RISK FACTOR; SEROLOGY;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES; AQUAPORIN 4; DIAGNOSIS, DIFFERENTIAL; ENCEPHALOMYELITIS, ACUTE DISSEMINATED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELITIS, TRANSVERSE; NEUROIMAGING; NEUROMYELITIS OPTICA; NOOTROPIC AGENTS; PROGNOSIS; RECURRENCE;

EID: 84881654907     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000433289.38339.a2     Document Type: Review

References (53)

1. Young NP, Weinshenker BG, Parisi JE, et al. Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain 2010;133(pt 2):333-348.
2. Krupp LB, Banwell B, Tenembaum S; International Pediatric MSSG. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68(16 suppl 2):S7-S12.
3. Kesselring J, Miller DH, Robb SA, et al. Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain 1990;113(pt 2): 291-302.
4. Rossi A. Imaging of acute disseminated encephalomyelitis. Neuroimaging Clin N Am 2008;18(1):149-161.
5. Weinshenker BG, Lucchinetti CF. Acute leukoencephalopathies: differential diagnosis and investigation. Neurologist 1998;4:148-166.
6. Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol 2005;62(11):1673-1680.
7. Tenembaum S, Chitnis T, Ness J, et al. Acute disseminated encephalomyelitis. Neurology 2007;68(16 suppl 2):S23-S36.
8. Bhat A, Naguwa S, Cheema G, Gershwin ME. The epidemiology of transverse myelitis. Autoimmun Rev 2010;9(5):A395-A399.
9. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002;59(4):499-505.
10. Frohman EM, Wingerchuk DM. Transverse myelitis. N Engl J Med 2010; 363(6):564-572.
11. Scott TF, Frohman EM, De Seze J, et al. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77(24):2128-2134.
12. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6(9):805-815.
13. Kitley JL, Leite MI, George JS, Palace JA. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012;18(3):271-285.
14. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302.
15. Bourre B, Zéphir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse myelitis. Arch Neurol 2012;69(3): 357-362.
16. Ringelstein M, Metz I, Ruprecht K, et al. Diagnostic biopsy of spinal tumours: need for prior aquaporin-4 antibody testing. MSJ 2012;18(S4):69-70.
17. Acchiote P. Sur un cas de neuromyelite subaigue ou maladie de Devic. Bulletin officiels de la Societe de neurologie de Paris 1907a;8-9:273-275.
18. Miyazawa I, Fujihara K, Itoyama Y. Eugene Devic (1858-1930). J Neurol 2002;249(3): 351-352.
19. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451): 2106-2112.
20. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6(7):383-392.
21. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5):1107-1114.
22. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10):1485-1489.
23. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
24. Matiello M, Kim HJ, Kim W, et al. Familial neuromyelitis optica. Neurology 2010;75(4): 310-315.
25. Lucchinetti CFMR, McGavern D, Bruck W, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125(pt 7):1450-1461.
26. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66(5):630-643.
27. Kinoshita M, Nakatsuji Y, Kimura T, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 2010;394(1):205-210.
28. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16(4):406-412.
29. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Nat Acad Sci U S A 2011;108(9): 3701-3706.
30. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 2012;72(1):53-64.
31. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135(pt 6):1834-1849.
32. Popescu BFG, Lennon VA, Parisi JE, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 2011;76(14): 1229-1237.
33. Kanbayashi T, Shimohata T, Nakashima I, et al. Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009;66(12):1563-1566.
34. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non-organ-specific autoimmunity. Arch Neurol 2008;65(1):78-83.
35. Kister I, Gulati S, Boz C, et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006;63(6):851-856.
36. Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63(3):390-396.
37. Magaña SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72(8):712-717.
38. Klawiter EC, Alvarez E 3rd, Xu J, et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 2009; 72(12):1101-1113.
39. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78(9):665-671.
40. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130(pt 2):1194-1205.
41. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions in neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130(pt 5):1224-1234.
42. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60(5):848-853.
43. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68(8):603-605.
44. Collongues N, Cabre P, Marignier R, et al. A benign form of neuromyelitis optica: does it exist? Arch Neurol 2011;68(7):918-994.
45. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010;67(8): 1016-1017.
46. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69(2):239-245.
47. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18(1):113-115.
48. Kimbough D, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012;1(4):180-187.
49. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 2012;11(6):525-544.
50. Pittock SJ, McKeon A, Mandrekar JN, et al. Pilot trial of eculizumab in AQP4-IgG-positive NMO. Boston, MA: American Neurological Association, 2012.
51. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71(3):314-322.
52. Tradtrantip L, Zhang H, Anderson MO, et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J 2012;26(5):2197-2208.
53. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2012. doi: 10.1002/ana.23741.